Braftovi (encorafenib) — Medica
Appendiceal Adenocarcinoma
Initial criteria
- age ≥ 18 years
- patient has BRAF V600E mutation-positive disease
- patient has advanced or metastatic disease
- the medication will be used in combination with Erbitux (cetuximab) or Vectibix (panitumumab)
Approval duration
1 year